NCT03971357

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Prospective Randomized Study to Determine Whether Use of Rhopressa™ Accelerates Corneal Clearing After Removal of Descemet Membrane for Treatment of Fuchs Dystrophy

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Price Vision Group · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.

Detailed description

Subjects with Fuchs endothelial dystrophy will have the central corneal endothelium and guttae-covered Descemet membrane surgically removed. Subjects will be randomized to use netarsudil or placebo eye drops once daily. Visual acuity, corneal clearing and central endothelial cell density will be monitored for the 3-month study duration.

Conditions

• Fuchs' Endothelial Dystrophy

Interventions

Type	Name	Description
DRUG	Netarsudil	netarsudil opthalmic solution 0.02%
DRUG	Placebo	Placebo eye drops

Timeline

• Start date: 2019-07-22
• Primary completion: 2021-08-26
• Completion: 2021-08-26
• First posted: 2019-06-03
• Last updated: 2023-02-06
• Results posted: 2023-02-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study